Five-fraction pancreatic SBRT with 30 Gy elective nodal irradiation feasible in phase I

Among 12 patients, pancreatic SBRT with 30 Gy elective nodal irradiation produced one acute dose-limiting event and three grade 3 cholangitis events.

KEY POINTS

  • This prospective, single-arm phase I trial (UMIN000044754) from Tohoku University Hospital, Japan, investigated five-fraction SBRT with elective nodal irradiation (ENI) in 12 patients with borderline resectable (n=4) or unresectable locally advanced (n=8) pancreatic adenocarcinoma. Median age was 64.5 years, median tumor diameter was 3.6 cm, and 11/12 patients (91.7%) had received systemic chemotherapy before irradiation, predominantly gemcitabine/nab-paclitaxel or FOLFIRINOX.
  • The treatment protocol combined an escalating primary tumor dose with fixed-dose ENI. All patients received 30 Gy in five fractions to high-risk elective regions surrounding the celiac artery and superior mesenteric artery, generally using a 7-mm anatomical expansion. Additional vessels could be included depending on tumor location and infiltration. The primary tumor prescription was escalated through 35 Gy, 37.5 Gy, and 40 Gy in five fractions, with six, three, and three patients treated at these levels, respectively.
  • Treatment was delivered using either conventional or MR-guided SBRT. Eight patients were treated using a conventional linac with fiducial-based breath-hold irradiation, and four received treatment on a 1.5-T MR-linac. Simultaneous integrated boost planning was used, with individualized adjustments to the gross tumor dose and strict prioritization of gastrointestinal OAR constraints. The median maximum GTV dose was 49.9 Gy, while median maximum stomach and duodenal doses were 29.9 Gy each.
  • The maximum tolerated dose was not reached within the tested dose levels. One patient treated at 35 Gy in five fractions developed grade 3 anorexia and nausea requiring hospitalization, meeting the predefined dose-limiting toxicity criterion. No dose-limiting toxicities were observed in the higher-dose cohorts, and all 12 patients completed SBRT without interruption. However, dose-limiting toxicity was assessed only during the first 14 days after treatment, limiting conclusions about subsequent safety.
  • Three patients developed grade 3 cholangitis during the subacute period, occurring approximately 1–3 months after SBRT. All three had pre-existing plastic biliary stents and required hospitalization, antibiotics, and stent replacement. The relationship between radiation and cholangitis could not be determined. No grade ≥3 late gastrointestinal toxicity, including ulceration, perforation, or bleeding, was reported during available follow-up.
  • Early disease-control outcomes were encouraging but highly preliminary. Median overall survival was 17.3 months from SBRT initiation (95% CI 5.9–29.2 months) and 26.7 months from initial diagnosis. Median progression-free survival after SBRT was 6.73 months, while one-year locoregional control was 75.0% (95% CI 37.7–93.7%). Ten patients developed progression, with nine experiencing distant metastases and three experiencing primary tumor progression, including overlapping failure events. Four patients underwent surgery within one month after SBRT.
  • The study cannot establish the optimal dose or benefit of elective nodal irradiation. The small 3+3 design was intended to assess acute safety rather than treatment efficacy, and no comparison with tumor-only SBRT was performed. Systemic treatment and surgery after SBRT were heterogeneous, while gastrointestinal constraints sometimes required compromised target coverage. The absence of an observed MTD does not mean that 40 Gy in five fractions is a validated recommended dose or that ENI improves disease control.

CLINICAL TAKEAWAY

Five-fraction pancreatic SBRT combining up to 40 Gy to the primary tumor with simultaneous 30 Gy elective nodal irradiation was feasible in this small phase I cohort. However, the narrow acute toxicity assessment window and three subsequent grade 3 cholangitis events, all in patients with biliary stents, warrant caution. Larger prospective studies are needed to determine the optimal treatment volumes, dose, safety, and clinical benefit of adding ENI.

SOURCE

Radiotherapy and Oncology

Browse more research Suggest a correction